Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by
selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) protein,
at the gene expression level. This study is a double-blind, randomized, placebo-controlled
Phase I study. The primary objective of the study is to assess the safety and tolerability of
single and multiple inhaled doses of TRK-250 in subjects with idiopathic pulmonary fibrosis
(IPF).